{"id":21056,"date":"2026-07-29T10:20:21","date_gmt":"2026-07-29T01:20:21","guid":{"rendered":"https:\/\/tomorrowaccess.com\/?page_id=21056"},"modified":"2026-10-27T14:19:56","modified_gmt":"2026-10-27T05:19:56","slug":"braveheart-2026","status":"publish","type":"page","link":"https:\/\/tomorrowaccess.com\/en\/s-1-journal\/braveheart-2026","title":{"rendered":"It Didn&rsquo;t Invent the Drug. It Didn&rsquo;t Run the Trials. It In-Licensed the Rest-of-World Rights."},"content":{"rendered":"<style>@import url('https:\/\/fonts.googleapis.com\/css2?family=Newsreader:ital,opsz,wght@0,6..72,400;0,6..72,500;0,6..72,600;1,6..72,400&display=swap');html,body {max-width: 100vw !important;overflow-x: hidden !important;}main,main > .entry-content,main > .wp-block-post-content,main > .wp-block-post-content.is-layout-constrained,main > .wp-block-post-content.is-layout-constrained > *,main .wp-block-group,main .wp-block-post-content {max-width: 100% !important;padding-left: 0 !important;padding-right: 0 !important;margin-left: 0 !important;margin-right: 0 !important;}main#wp--skip-link--target {padding: 0 !important;margin-top: 0 !important;max-width: 100% !important;}.s1-figure-inline {display: block;width: 100%;max-width: 100%;margin: 60px 0;padding: 0;box-sizing: border-box;}.s1-figure-inline picture {display: block;width: 100%;}.s1-figure-inline img {display: block;width: 100%;max-width: 100%;height: auto;margin: 0;}@media (max-width: 720px) {.s1-hero-grid {grid-template-columns: 1fr !important;}.s1-hero-grid > div {border-right: none !important;border-bottom: 1px solid #e6e6e6 !important;padding: 24px 12px !important;}.s1-hero-grid > div:last-child {border-bottom: none !important;}.s1-hero-grid > div > div:first-child {font-size: 32px !important;white-space: normal !important;}.s1-body-table,.s1-body-table tbody,.s1-body-table tr,.s1-body-table td,.s1-body-table th {display: block !important;width: 100% !important;max-width: 100% !important;box-sizing: border-box !important;}.s1-body-table thead {display: none !important;}.s1-body-table tr {margin-bottom: 16px !important;padding: 8px 0 !important;border-top: 1px solid #1a1a1a !important;}.s1-body-table tr:last-child {border-bottom: 1px solid #1a1a1a !important;}.s1-body-table td {text-align: left !important;padding: 6px 8px !important;}.s1-light-shadow {flex-direction: column !important;}.s1-light-shadow > div {border-left: 1px solid #1a1a1a !important;border-top: 0 !important;}.s1-light-shadow > div:first-child {border-top: 1px solid #1a1a1a !important;}h1 {font-size: clamp(26px, 7vw, 34px) !important;}h2 {font-size: clamp(22px, 5.5vw, 28px) !important;}.s1-article-cta-headline {font-size: 24px !important; line-height: 1.4 !important;}}@media (max-width: 480px) {.s1-article-cta-headline {font-size: 20px !important;}}main .wp-block-post-content>.alignfull{margin-left:calc(-1*var(--wp--style--root--padding-left,20px)) !important;margin-right:calc(-1*var(--wp--style--root--padding-right,20px)) !important;max-width:none !important;width:auto !important;}<\/style>\n<div class=\"alignfull\" style=\"font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; color: #1a1a1a; overflow-wrap: break-word; text-wrap: pretty; font-size: 16px; -webkit-font-smoothing: antialiased; background: #fafafa; width: 100%;\">\n<div style=\"max-width: 1000px; margin: 0 auto; padding: 80px 20px 0; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif;\">\n  <a href=\"https:\/\/tomorrowaccess.com\/en\/s-1-journal\/\" style=\"text-decoration: none; color: inherit; display: block;\"><\/p>\n<div style=\"text-align: left; margin-bottom: 40px;\">\n<div style=\"width: 100%; height: 5px; background: #1a1a1a;\"><\/div>\n<div style=\"margin-top: 26px; font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 32px; font-weight: 600; color: #1a1a1a; letter-spacing: 0.01em; line-height: 1; margin-bottom: 14px;\">S-1 <span style=\"color: #daa241;\">Journal<\/span><\/div>\n<div style=\"display: flex; align-items: center; flex-wrap: wrap; gap: 14px; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; margin-bottom: 26px;\">\n        <span style=\"font-size: 11px; letter-spacing: 0.18em; color: #1a1a1a; font-weight: 700; text-transform: uppercase;\">The 10 Questions<\/span><br \/>\n        <span style=\"font-size: 11px; color: #ccc;\">|<\/span><br \/>\n        <span style=\"font-size: 12px; letter-spacing: 0.02em; color: #666; font-weight: 400;\">Every S-1, decoded through the same 10 questions.<\/span>\n      <\/div>\n<div style=\"width: 100%; height: 1px; background: #daa241;\"><\/div>\n<\/p><\/div>\n<p>  <\/a>\n<\/div>\n<div style=\"max-width: 720px; margin: 0 auto; padding: 0 20px; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; color: #1a1a1a; overflow-wrap: break-word; text-wrap: pretty;\">\n<div style=\"margin: 0 0 32px 0;\">\n<p style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 30px; font-weight: 600; letter-spacing: 0; color: #daa241; margin: 0; line-height: 1.2;\">Braveheart Bio<\/p>\n<\/div>\n<h1 style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: clamp(32px, 6vw, 46px); font-weight: 600; line-height: 1.2; letter-spacing: -0.01em; color: #000; margin: 0 0 40px 0; text-wrap: pretty;\">It Didn&rsquo;t Invent the Drug. It Didn&rsquo;t Run the Trials.<br \/>It In-Licensed the Rest-of-World Rights.<\/h1>\n<div style=\"font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 13px; letter-spacing: 0.03em; color: #888; margin: 0 0 60px 0; border-bottom: 1px solid #e6e6e6; padding-bottom: 16px;\">Source: <a href=\"https:\/\/www.sec.gov\/Archives\/edgar\/data\/2131524\/000162828026048213\/braveheartbioinc-sx1.htm\" target=\"_blank\" rel=\"noopener\" style=\"color: #daa241; text-decoration: underline; text-underline-offset: 3px; text-decoration-thickness: 1px;\">Braveheart Bio, Inc. S-1 (filed 2026-07-14) \u2197<\/a><\/div>\n<p style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 20px; line-height: 1.65; letter-spacing: 0; color: #1a1a1a; margin: 0 0 1.5em 0;\">In 2026, a company called Braveheart Bio filed its <span style=\"white-space:nowrap;\">S-1<\/span>, the registration statement a company must file with U.S. securities regulators before going public. What it wants to do is treat a disease in which the heart muscle grows too thick, using a pill. The drug at the center of that plan, however, is <strong style=\"font-weight: 700; color: #000;\">not one the company made<\/strong>. It is a drug discovered by a Chinese pharmaceutical company, obtained under a license.<\/p>\n<p style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 20px; line-height: 1.65; letter-spacing: 0; color: #1a1a1a; margin: 0 0 1.5em 0;\">Braveheart has <strong style=\"font-weight: 700; color: #000;\">never run the human trials<\/strong> of that drug, either. The chemistry and the testing were both done by the Chinese company, Hengrui. What Braveheart licensed was the drug, the data from those trials, and the exclusive right to develop and sell it everywhere in the world <strong style=\"font-weight: 700; color: #000;\">outside Greater China<\/strong>, meaning mainland China, Hong Kong, Macau, and Taiwan.<\/p>\n<\/div>\n<div style=\"max-width: 720px; margin: 80px auto; padding: 0 20px;\">\n<div class=\"s1-hero-grid\" style=\"border-top: 1px solid #1a1a1a; border-bottom: 1px solid #1a1a1a; padding: 50px 0; display: grid; grid-template-columns: repeat(3, 1fr); gap: 0; text-align: center; align-items: start;\">\n<div style=\"padding: 0 12px; border-right: 1px solid #e6e6e6;\">\n<div style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: clamp(28px, 4.5vw, 36px); font-weight: 500; line-height: 1.05; color: #000; letter-spacing: -0.02em; white-space: nowrap;\">$58.2M<\/div>\n<div style=\"font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 10.5px; letter-spacing: 0.2em; color: #daa241; margin-top: 18px; font-weight: 700; text-transform: uppercase;\">PAID TO HENGRUI UPFRONT<\/div>\n<div style=\"font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 12px; letter-spacing: 0.04em; color: #888; margin-top: 6px; font-weight: 400; line-height: 1.4;\">cash plus stock, at signing<\/div>\n<\/p><\/div>\n<div style=\"padding: 0 12px; border-right: 1px solid #e6e6e6;\">\n<div style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: clamp(28px, 4.5vw, 36px); font-weight: 500; line-height: 1.05; color: #000; letter-spacing: -0.02em; white-space: nowrap;\">up to $1.0B<\/div>\n<div style=\"font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 10.5px; letter-spacing: 0.2em; color: #daa241; margin-top: 18px; font-weight: 700; text-transform: uppercase;\">COMMERCIAL MILESTONES<\/div>\n<div style=\"font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 12px; letter-spacing: 0.04em; color: #888; margin-top: 6px; font-weight: 400; line-height: 1.4;\">if specified milestones are achieved<\/div>\n<\/p><\/div>\n<div style=\"padding: 0 12px;\">\n<div style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: clamp(28px, 4.5vw, 36px); font-weight: 500; line-height: 1.05; color: #000; letter-spacing: -0.02em; white-space: nowrap;\">0<\/div>\n<div style=\"font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 10.5px; letter-spacing: 0.2em; color: #daa241; margin-top: 18px; font-weight: 700; text-transform: uppercase;\">DESIGNED OR OVERSEEN<\/div>\n<div style=\"font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 12px; letter-spacing: 0.04em; color: #888; margin-top: 6px; font-weight: 400; line-height: 1.4;\">none by Braveheart, to date<\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/div>\n<div style=\"max-width: 720px; margin: 0 auto; padding: 0 20px; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; color: #1a1a1a; overflow-wrap: break-word; text-wrap: pretty;\">\n<p style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 20px; line-height: 1.65; letter-spacing: 0; color: #1a1a1a; margin: 60px 0 1.5em 0;\">The money runs like this. Upfront consideration of <strong style=\"font-weight: 700; color: #000;\"><span style=\"white-space:nowrap;\">$58.2<\/span> million<\/strong> has already gone to Hengrui: <span style=\"white-space:nowrap;\">$32.5<\/span> million in cash, plus 32.5 million shares of <span style=\"white-space:nowrap;\">non-voting<\/span> preferred stock with an estimated fair value of <span style=\"white-space:nowrap;\">$25.7<\/span> million. Beyond that, up to <span style=\"white-space:nowrap;\">$23.0<\/span> million is payable as <span style=\"white-space:nowrap;\">technology-transfer<\/span> and development milestones are met, part of which has already been achieved and paid, and <strong style=\"font-weight: 700; color: #000;\">up to <span style=\"white-space:nowrap;\">$1.0<\/span> billion<\/strong> upon achievement of specified commercial milestones. On top of those, Hengrui receives <span style=\"white-space:nowrap;\">5%<\/span> to <span style=\"white-space:nowrap;\">10%<\/span> of Braveheart&rsquo;s total annual net sales of the drug, for a defined term.<\/p>\n<p style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 20px; line-height: 1.65; letter-spacing: 0; color: #1a1a1a; margin: 0 0 1.5em 0;\">The company sells nothing yet, and its accumulated deficit stands at about <span style=\"white-space:nowrap;\">$80.3<\/span> million. Cash was about <span style=\"white-space:nowrap;\">$80.6<\/span> million at the end of March. This is a U.S. startup that <span style=\"white-space:nowrap;\">in-licensed<\/span> a <span style=\"white-space:nowrap;\">Chinese-born<\/span> drug, and is about to take it into the pivotal trials it has never once run itself.<\/p>\n<p style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 20px; line-height: 1.65; letter-spacing: 0; color: #1a1a1a; margin: 0 0 1.4em 0;\">Ten questions. We lay out only what the S-1 says.<\/p>\n<div class=\"s1-toc-top\" style=\"margin: 60px 0; padding: 30px; background: #fafafa; border-top: 1px solid #e6e6e6; border-bottom: 1px solid #e6e6e6; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif;\"><div style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 13px; color: #daa241; letter-spacing: 0.22em; margin-bottom: 16px;\">CONTENTS<\/div><ul style=\"list-style: none; padding: 0; margin: 0 0 20px; font-size: 14px;\"><li style=\"padding: 9px 0; border-bottom: 1px solid #e6e6e6; display: flex; align-items: baseline; gap: 16px; color: #000000;\"><span style=\"color: #daa241; font-weight: 700; min-width: 60px; font-family: 'Newsreader', Georgia, 'Times New Roman', serif;\">Q1<\/span><span>What is this company, really?<\/span><\/li><li style=\"padding: 9px 0; border-bottom: 1px solid #e6e6e6; display: flex; align-items: baseline; gap: 16px; color: #000000;\"><span style=\"color: #daa241; font-weight: 700; min-width: 60px; font-family: 'Newsreader', Georgia, 'Times New Roman', serif;\">Q2<\/span><span>What is it competing on?<\/span><\/li><li style=\"padding: 9px 0; border-bottom: 1px solid #e6e6e6; display: flex; align-items: baseline; gap: 16px; color: #666666;\"><span style=\"color: #daa241; font-weight: 700; min-width: 60px; font-family: 'Newsreader', Georgia, 'Times New Roman', serif;\">Q3<\/span><span>How big is the market?<\/span><\/li><li style=\"padding: 9px 0; border-bottom: 1px solid #e6e6e6; display: flex; align-items: baseline; gap: 16px; color: #666666;\"><span style=\"color: #daa241; font-weight: 700; min-width: 60px; font-family: 'Newsreader', Georgia, 'Times New Roman', serif;\">Q4<\/span><span>Who uses it?<\/span><\/li><li style=\"padding: 9px 0; border-bottom: 1px solid #e6e6e6; display: flex; align-items: baseline; gap: 16px; color: #666666;\"><span style=\"color: #daa241; font-weight: 700; min-width: 60px; font-family: 'Newsreader', Georgia, 'Times New Roman', serif;\">Q5<\/span><span>How does it make money?<\/span><\/li><li style=\"padding: 9px 0; border-bottom: 1px solid #e6e6e6; display: flex; align-items: baseline; gap: 16px; color: #666666;\"><span style=\"color: #daa241; font-weight: 700; min-width: 60px; font-family: 'Newsreader', Georgia, 'Times New Roman', serif;\">Q6<\/span><span>Are the numbers healthy?<\/span><\/li><li style=\"padding: 9px 0; border-bottom: 1px solid #e6e6e6; display: flex; align-items: baseline; gap: 16px; color: #666666;\"><span style=\"color: #daa241; font-weight: 700; min-width: 60px; font-family: 'Newsreader', Georgia, 'Times New Roman', serif;\">Q7<\/span><span>Who runs it?<\/span><\/li><li style=\"padding: 9px 0; border-bottom: 1px solid #e6e6e6; display: flex; align-items: baseline; gap: 16px; color: #666666;\"><span style=\"color: #daa241; font-weight: 700; min-width: 60px; font-family: 'Newsreader', Georgia, 'Times New Roman', serif;\">Q8<\/span><span>Who controls it?<\/span><\/li><li style=\"padding: 9px 0; border-bottom: 1px solid #e6e6e6; display: flex; align-items: baseline; gap: 16px; color: #666666;\"><span style=\"color: #daa241; font-weight: 700; min-width: 60px; font-family: 'Newsreader', Georgia, 'Times New Roman', serif;\">Q9<\/span><span>What does it fear?<\/span><\/li><li style=\"padding: 9px 0; border-bottom: 1px solid #e6e6e6; display: flex; align-items: baseline; gap: 16px; color: #666666;\"><span style=\"color: #daa241; font-weight: 700; min-width: 60px; font-family: 'Newsreader', Georgia, 'Times New Roman', serif;\">Q10<\/span><span>What happens to the money raised?<\/span><\/li><li style=\"padding: 9px 0;  display: flex; align-items: baseline; gap: 16px; color: #666666;\"><span style=\"color: #daa241; font-weight: 700; min-width: 60px; font-family: 'Newsreader', Georgia, 'Times New Roman', serif;\">\u2014<\/span><span>Closing: beyond the ten questions<\/span><\/li><\/ul><p style=\"margin: 0; font-size: 13px; color: #666666; line-height: 1.7;\">Q1 and Q2 are free. Q3 onward is a one-time $25 unlock. <a href=\"https:\/\/buy.stripe.com\/8x2dR88febsX2Ov62T67S0n?client_reference_id=braveheart-en\" style=\"color: #daa241; font-weight: 700; text-decoration: none; white-space: nowrap;\">Unlock the full piece for $25 &rarr;<\/a><\/p><\/div><p style=\"font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 13px; letter-spacing: 0.22em; font-weight: 700; color: #daa241; margin: 100px 0 12px 0; text-transform: uppercase;\">Question 1<\/p>\n<h2 style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: clamp(26px, 5vw, 32px); font-weight: 600; line-height: 1.25; letter-spacing: -0.005em; color: #000; margin: 0 0 28px 0;\">What is this company, really?<\/h2>\n<div style=\"margin: 0 0 30px 0; padding: 0 0 16px 0; border-bottom: 1px solid #1a1a1a;\">\n<p style=\"font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 12px; letter-spacing: 0.2em; color: #daa241; font-weight: 700; margin: 0 0 8px 0; text-transform: uppercase;\">Primary source \u00b7 from the S-1<\/p>\n<p style=\"font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 15px; line-height: 1.6; color: #1a1a1a; margin: 0;\">Prospectus Summary (Overview), Business (Overview) \u2014 from the S-1<\/p>\n<\/div>\n<p style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 20px; line-height: 1.65; letter-spacing: 0; color: #1a1a1a; margin: 0 0 1.5em 0;\">In one line: a company carrying a Chinese heart drug to the rest of the world.<\/p>\n<p style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 20px; line-height: 1.65; letter-spacing: 0; color: #1a1a1a; margin: 0 0 1.5em 0;\">Hypertrophic cardiomyopathy (HCM) is a disease in which the heart muscle thickens abnormally. When the walls grow thick, the heart may have trouble relaxing and filling, and in the obstructive form, the flow of blood out of the heart can be restricted as well. People get short of breath and feel their heart pound; in severe cases it can lead to heart failure or sudden cardiac death. It affects <strong style=\"font-weight: 700; color: #000;\">more than 700,000 people<\/strong> in the United States alone, the company writes.<\/p>\n<p style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 20px; line-height: 1.65; letter-spacing: 0; color: #1a1a1a; margin: 0 0 1.5em 0;\">The company&rsquo;s drug, <span style=\"white-space:nowrap;\">BHB-1893<\/span>, is an oral drug meant to ease the thickened heart&rsquo;s tendency to squeeze too hard. It belongs to a class that <strong style=\"font-weight: 700; color: #000;\">damps the contraction of the heart muscle<\/strong>, and it is being developed both for the form in which the outflow of blood is obstructed and for the form in which it is not.<\/p>\n<p style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 20px; line-height: 1.65; letter-spacing: 0; color: #1a1a1a; margin: 0 0 1.5em 0;\">The heart of the story is where this drug came from. <span style=\"white-space:nowrap;\">BHB-1893<\/span> was <strong style=\"font-weight: 700; color: #000;\">discovered and developed by the Chinese pharmaceutical company Hengrui<\/strong>, which calls it <strong style=\"font-weight: 700; color: #000;\"><span style=\"white-space:nowrap;\">HRS-1893<\/span><\/strong> in China. In September 2025, Braveheart obtained it under <strong style=\"font-weight: 700; color: #000;\">an exclusive license<\/strong>.<\/p>\n<p style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 20px; line-height: 1.65; letter-spacing: 0; color: #1a1a1a; margin: 0 0 1.5em 0;\">At the front of the <span style=\"white-space:nowrap;\">S-1<\/span>, the company states what it is aiming for.<\/p>\n<blockquote style=\"position: relative; margin: 36px 0; padding: 20px 22px 16px 22px; background: #f5f1e6; box-sizing: border-box; max-width: 100%; overflow: hidden;\"><p>\n<span aria-hidden=\"true\" style=\"position: absolute; top: 2px; left: 10px; font-family: Georgia, 'Times New Roman', serif; font-size: 42px; font-weight: 400; color: #daa241; line-height: 1;\">&ldquo;<\/span><\/p>\n<p style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 17px; font-weight: 400; line-height: 1.65; letter-spacing: 0.02em; color: #1a1a1a; margin: 0 0 10px 0; padding-left: 24px; overflow-wrap: break-word; overflow-wrap: break-word;\">Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.<\/p>\n<p style=\"font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 9.5px; font-weight: 700; letter-spacing: 0.16em; color: #daa241; margin: 0; padding-left: 24px; overflow-wrap: anywhere;\">BRAVEHEART BIO S-1 (2026) \u2014 PROSPECTUS SUMMARY<\/p>\n<\/blockquote>\n<p style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 20px; line-height: 1.65; letter-spacing: 0; color: #1a1a1a; margin: 0 0 1.5em 0;\">One thing should be made clear before going further. <span style=\"white-space:nowrap;\">BHB-1893<\/span> is an <strong style=\"font-weight: 700; color: #000;\">investigational candidate<\/strong>, not an approved medicine: the filing states plainly that the company does not have any products approved for sale. This article does not recommend its efficacy or safety. Every figure that follows comes from trials run by Hengrui or from what is written in the filing.<\/p>\n<p style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 20px; line-height: 1.65; letter-spacing: 0; color: #1a1a1a; margin: 0 0 1.5em 0;\">A <span style=\"white-space:nowrap;\">clinical-stage<\/span> company taking an oral heart drug born in China out to the world.<\/p>\n<p style=\"font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 13px; letter-spacing: 0.22em; font-weight: 700; color: #daa241; margin: 100px 0 12px 0; text-transform: uppercase;\">Question 2<\/p>\n<h2 style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: clamp(26px, 5vw, 32px); font-weight: 600; line-height: 1.25; letter-spacing: -0.005em; color: #000; margin: 0 0 28px 0;\">What does it compete on?<\/h2>\n<div style=\"margin: 0 0 30px 0; padding: 0 0 16px 0; border-bottom: 1px solid #1a1a1a;\">\n<p style=\"font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 12px; letter-spacing: 0.2em; color: #daa241; font-weight: 700; margin: 0 0 8px 0; text-transform: uppercase;\">Primary source \u00b7 from the S-1<\/p>\n<p style=\"font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 15px; line-height: 1.6; color: #1a1a1a; margin: 0;\">Business (Competitive Strengths) \u2014 from the S-1<\/p>\n<\/div>\n<p style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 20px; line-height: 1.65; letter-spacing: 0; color: #1a1a1a; margin: 0 0 1.5em 0;\">The case for this drug rests on three claims. Take them in turn.<\/p>\n<p style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 20px; line-height: 1.65; letter-spacing: 0; color: #1a1a1a; margin: 0 0 1.5em 0;\">The strengths the company puts forward fall into three groups: the weakness of the drugs that got there first, ease of use, and the quality of the effect. Start with the two rival drugs already on the market.<\/p>\n<h3 style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 22px; font-weight: 700; line-height: 1.5; color: #000; margin: 30px 0 16px 0; border-left: 4px solid #daa241; padding: 0 0 0 16px;\">The rival drugs carry an &ldquo;<strong style=\"font-weight: 700; color: #000;\">LVEF cost<\/strong>&rdquo;<\/h3>\n<p style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 20px; line-height: 1.65; letter-spacing: 0; color: #1a1a1a; margin: 0 0 1.5em 0;\">Two drugs of the same class were approved before this one: <strong style=\"font-weight: 700; color: #000;\">mavacamten<\/strong> (sold as Camzyos) and <strong style=\"font-weight: 700; color: #000;\">aficamten<\/strong> (sold as MYQORZO). Both lower the obstruction at the heart&rsquo;s outflow. But as the dose goes up, the company says, the heart&rsquo;s ability to push blood out falls along with it.<\/p>\n<p style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 20px; line-height: 1.65; letter-spacing: 0; color: #1a1a1a; margin: 0 0 1.5em 0;\">The company calls this the &ldquo;<strong style=\"font-weight: 700; color: #000;\">LVEF cost<\/strong>,&rdquo; the price paid in lost pumping power. Its point is that pumping power can slide toward an unsafe level before the obstruction has been brought all the way down, leaving some people still symptomatic. In the pivotal trials of those earlier drugs, the share of patients whose obstruction fell to the target was <strong style=\"font-weight: 700; color: #000;\"><span style=\"white-space:nowrap;\">49%<\/span><\/strong> on <strong style=\"font-weight: 700; color: #000;\">aficamten<\/strong> and <span style=\"white-space:nowrap;\">57%<\/span> on <strong style=\"font-weight: 700; color: #000;\">mavacamten<\/strong>. The two figures come from two different trials, measured at different points and against differently defined targets, so they are not a <span style=\"white-space:nowrap;\">like-for-like<\/span> comparison.<\/p>\n<p style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 20px; line-height: 1.65; letter-spacing: 0; color: #1a1a1a; margin: 0 0 1.5em 0;\">On top of that, because of the worry about losing pumping power, the dose must be raised in a careful, <span style=\"white-space:nowrap;\">multi-step<\/span> process, and the heart must be <strong style=\"font-weight: 700; color: #000;\">checked frequently by ultrasound<\/strong>. That burden has held back <span style=\"white-space:nowrap;\">real-world<\/span> uptake, the company argues.<\/p>\n<div class=\"s1-paywall-fade\" aria-hidden=\"true\" style=\"position:relative; height:0; overflow:visible;\"><div style=\"position:absolute; left:0; right:0; bottom:0; height:220px; background:linear-gradient(to bottom, rgba(250,250,250,0) 0%, rgba(250,250,250,0.55) 45%, rgba(250,250,250,0.9) 80%, #fafafa 100%); pointer-events:none;\"><\/div><\/div><div class=\"s1-paywall-cta\" style=\"margin: 60px 0; padding: 60px 30px; background: #fafafa; border-top: 2px solid #daa241; border-bottom: 1px solid #e6e6e6; text-align: center; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif;\">\n\n  <div style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 13px; color: #daa241; letter-spacing: 0.22em; margin-bottom: 16px;\">CONTINUE READING<\/div>\n\n  <h3 style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 28px; font-weight: 400; line-height: 1.5; color: #000; margin: 0 0 32px; letter-spacing: 0.02em;\">\n    Keep reading\n  <\/h3>\n\n  <ul style=\"list-style: none; padding: 0; margin: 0 auto 32px; max-width: 380px; text-align: left; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px;\">\n      <li style=\"padding: 10px 0; border-bottom: 1px solid #e6e6e6; display: flex; align-items: baseline; gap: 16px;\">\n        <span style=\"color: #daa241; font-weight: 700; min-width: 54px; font-family: 'Newsreader', Georgia, 'Times New Roman', serif;\">Q3<\/span>\n        <span>How big is the market?<\/span>\n      <\/li>      <li style=\"padding: 10px 0; border-bottom: 1px solid #e6e6e6; display: flex; align-items: baseline; gap: 16px;\">\n        <span style=\"color: #daa241; font-weight: 700; min-width: 54px; font-family: 'Newsreader', Georgia, 'Times New Roman', serif;\">Q4<\/span>\n        <span>Who actually uses it?<\/span>\n      <\/li>      <li style=\"padding: 10px 0; border-bottom: 1px solid #e6e6e6; display: flex; align-items: baseline; gap: 16px;\">\n        <span style=\"color: #daa241; font-weight: 700; min-width: 54px; font-family: 'Newsreader', Georgia, 'Times New Roman', serif;\">Q5<\/span>\n        <span>How does it make money?<\/span>\n      <\/li>      <li style=\"padding: 10px 0; border-bottom: 1px solid #e6e6e6; display: flex; align-items: baseline; gap: 16px;\">\n        <span style=\"color: #daa241; font-weight: 700; min-width: 54px; font-family: 'Newsreader', Georgia, 'Times New Roman', serif;\">Q6<\/span>\n        <span>Are the numbers healthy?<\/span>\n      <\/li>      <li style=\"padding: 10px 0; border-bottom: 1px solid #e6e6e6; display: flex; align-items: baseline; gap: 16px;\">\n        <span style=\"color: #daa241; font-weight: 700; min-width: 54px; font-family: 'Newsreader', Georgia, 'Times New Roman', serif;\">Q7<\/span>\n        <span>Who runs it?<\/span>\n      <\/li>      <li style=\"padding: 10px 0; border-bottom: 1px solid #e6e6e6; display: flex; align-items: baseline; gap: 16px;\">\n        <span style=\"color: #daa241; font-weight: 700; min-width: 54px; font-family: 'Newsreader', Georgia, 'Times New Roman', serif;\">Q8<\/span>\n        <span>Who controls it?<\/span>\n      <\/li>      <li style=\"padding: 10px 0; border-bottom: 1px solid #e6e6e6; display: flex; align-items: baseline; gap: 16px;\">\n        <span style=\"color: #daa241; font-weight: 700; min-width: 54px; font-family: 'Newsreader', Georgia, 'Times New Roman', serif;\">Q9<\/span>\n        <span>What is it afraid of?<\/span>\n      <\/li>      <li style=\"padding: 10px 0; border-bottom: 1px solid #e6e6e6; display: flex; align-items: baseline; gap: 16px;\">\n        <span style=\"color: #daa241; font-weight: 700; min-width: 54px; font-family: 'Newsreader', Georgia, 'Times New Roman', serif;\">Q10<\/span>\n        <span>What becomes of the money it raises?<\/span>\n      <\/li>      <li style=\"padding: 10px 0;  display: flex; align-items: baseline; gap: 16px;\">\n        <span style=\"color: #daa241; font-weight: 700; min-width: 54px; font-family: 'Newsreader', Georgia, 'Times New Roman', serif;\">Closing<\/span>\n        <span>Beyond the ten questions<\/span>\n      <\/li>\n  <\/ul>\n<div class=\"s1-owarini-teaser\" style=\"max-width: 720px; margin: 0 auto 30px; padding: 30px 0 0; border-top: 1px solid #e6e6e6; text-align: left; position: relative;\"><p style=\"font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 12px; letter-spacing: 0.25em; font-weight: 700; color: #daa241; margin: 0 0 12px; text-transform: uppercase;\">In closing<\/p><h4 style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 24px; font-weight: 400; line-height: 1.5; color: #000; margin: 0 0 30px; letter-spacing: 0.02em;\">Beyond the ten questions<\/h4><p style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 20px; line-height: 1.65; letter-spacing: 0; color: #000; margin: 0 0 24px;\">What Braveheart is selling is not just an oral heart drug. It is the arrangement itself: a drug discovered and developed by a Chinese company, then licensed to a young U.S. company to develop and commercialize everywhere outside Greater China. The $58.2 million paid at the start, and up to $1.0 billion in milestones if specified commercial targets are hit. A drug born in China, carried toward Western markets by a company now built around this one asset.<\/p><p style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 20px; line-height: 1.65; letter-spacing: 0; color: #000; margin: 0;\">But the party carrying it does not hold a single approved product.<\/p><div aria-hidden=\"true\" style=\"position: absolute; left: 0; right: 0; bottom: 0; height: 60px; background: linear-gradient(to bottom, rgba(250,250,250,0) 0%, rgba(250,250,250,0.85) 100%); pointer-events: none;\"><\/div><\/div>\n  <a href=\"https:\/\/buy.stripe.com\/8x2dR88febsX2Ov62T67S0n?client_reference_id=braveheart-en\" style=\"display: inline-block; background: #daa241; color: #fff; padding: 18px 48px; font-size: 16px; font-weight: 700; text-decoration: none; letter-spacing: 0.08em; transition: background 0.2s;\" onmouseover=\"this.style.background='#b88a36'\" onmouseout=\"this.style.background='#daa241'\">\n    Full access for $25 &rarr;\n  <\/a>\n\n  <div style=\"margin: 60px 0 0; text-align: left;\">\n    <a href=\"https:\/\/tomorrowaccess.com\/en\/s-1-journal\" style=\"font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 16px; font-weight: 700; color: #daa241; text-decoration: none; letter-spacing: 0.02em;\">&larr; Back to S-1 Journal<\/a>\n  <\/div>\n\n<\/div><div class=\"s1-paywall-locked\" aria-hidden=\"true\" style=\"display:none;\"><\/div><div class=\"s1-article-footer\" style=\"margin: 16px 0 0; padding: 8px 30px 36px; background: transparent; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 13px; color: #666; line-height: 1.8; text-align: center;\">\n  <div style=\"max-width: 680px; margin: 0 auto;\">\n    <p style=\"margin: 0 0 18px;\">This article is an explainer for informational purposes only. It is not investment advice or a solicitation to invest. Any investment decision is your own responsibility. The facts here are based on each company&rsquo;s S-1 filing but are not guaranteed to be accurate or complete. Please consult the primary filing on <a href=\"https:\/\/www.sec.gov\/cgi-bin\/browse-edgar?action=getcompany&type=S-1&dateb=&owner=include&count=40\" target=\"_blank\" rel=\"noopener\" style=\"color: #daa241; text-decoration: underline; text-underline-offset: 2px;\">SEC EDGAR<\/a>.<\/p>\n    <p style=\"margin: 0;\"><a href=\"https:\/\/tomorrowaccess.com\/en\/s-1-journal#sales-info\" style=\"color: #daa241; text-decoration: underline; text-underline-offset: 3px; font-weight: 700;\">Pricing &amp; terms &rarr;<\/a><\/p>\n  <\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>S-1 Journal The 10 Questions | Every S-1, decoded through the same 10 questions. Braveheart Bio It Didn&rsquo; [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":24365,"parent":20744,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_yoast_wpseo_focuskw":"Braveheart Bio S-1","_yoast_wpseo_title":"Braveheart Bio S-1: Never Ran a Trial of Its Own %%sep%% %%sitename%%","_yoast_wpseo_metadesc":"A U.S. startup licensed an oral heart drug discovered by a Chinese pharmaceutical company, taking exclusive rights everywhere outside Greater China, and is now going public. It has never designed or run a clinical trial itself. Zero revenue, an accumulated deficit of about $80.3 million, and a16z Bio among its backers. Decoded from the S-1.","_yoast_wpseo_canonical":"","_yoast_wpseo_opengraph-title":"","_yoast_wpseo_opengraph-description":"","_yoast_wpseo_twitter-title":"","_yoast_wpseo_twitter-description":"","_uag_custom_page_level_css":"","eventcal-data-date-start":"","eventcal-data-date-end":"","eventcal-data-url":"","eventcal-data-place":"","eventcal-data-capacity":"","eventcal-data-ticket":"","eventcal-data-report":"","eventcal-data-note":"","mentoring-company":"","mentoring-position":"","mentoring-name":"","mentoring-url":"","mentoring-text-top":"","mentoring-text-01":"","mentoring-text-02":"","mentoring-text-03":"","mentoring-images":"","mentoring-logo":"","expert-pitch-data-thumbnail":"https:\/\/www.youtube.com\/embed\/M7DlaXKYhLw","expert-pitch-data-youtube":"","expert-pitch-data-date":"2022.03.01 TUE 12:00-13:00","expert-pitch-data-name":"Global Brain, Partner US office \u4e00\u5bae \u7fd4\u5e73\u6c0f","expert-pitch-data-excerpt":"\u91d1\u878d\u5e02\u5834\u304c\u5927\u304d\u304f\u5909\u308f\u308d\u3046\u3068\u3057\u3066\u3044\u307e\u3059\u3002 \u3053\u308c\u307e\u3067\u306f\u65e7\u6765\u306e\u9280\u884c\u304c\u307b\u307c\u5168\u3066\u306e\u6a5f\u80fd\u3092\u6301\u3063\u3066\u3044\u307e\u3057\u305f\u304c\u3001\u304a\u91d1\u3092\u8caf\u3081\u308b\u3001\u9001\u91d1\u3059\u308b\u3001\u6c7a\u6e08\u3059\u308b\u3001\u306a\u3069\u306e\u6a5f\u80fd\u304c\u7d30\u5206\u5316\u3057\u3066\u3001\u3055\u307e\u3056\u307e\u306a\u4eba\u304c\u500b\u3005\u306e\u30b5\u30fc\u30d3\u30b9\u3092\u63d0\u4f9b\u3067\u304d\u308b\u6642\u4ee3\u306b\u306a\u308a\u307e\u3057\u305f\u3002 \u3055\u3089\u306bAI\u306e\u6280\u8853\u3084\u81a8\u5927\u306a\u91cf\u3092\u51e6\u7406\u3067\u304d\u308b\u6280\u8853\u3001\u30d6\u30ed\u30c3\u30af\u30c1\u30a7\u30fc\u30f3\u6280\u8853\u306a\u3069\u3082\u6210\u719f\u3057\u3066\u304d\u305f\u3053\u3068\u3082\u3042\u308a\u3001\u305d\u306e\u52d5\u304d\u306f\u52a0\u901f\u3057\u3066\u3044\u307e\u3059\u3002 \u52d5\u304d\u304c\u6fc0\u3057\u3044\u30d5\u30a3\u30f3\u30c6\u30c3\u30af\u306b\u3064\u3044\u3066\u3001\u6295\u8cc7\u304c\u6d3b\u767a\u3067\u3001\u4eca\u5e74\u306f\u30b0\u30ed\u30fc\u30d0\u30eb\u6295\u8cc7\u3068Fintech\u306a\u3069\u306b\u3082\u6ce8\u529b\u3055\u308c\u3066\u3044\u304fGlobal Brain Partner \u4e00\u5bae\u6c0f\u3068\u6700\u65b0\u60c5\u5831\u3092\u304a\u5c4a\u3051\u3057\u307e\u3059\u3002","expert-pitch-data-download-file":"","expert-pitch-data-peatix":"","expert-pitch-data-whitepaper-show":false,"common-label-text":"","_locale":"en_US","_original_post":"https:\/\/tomorrowaccess.com\/?page_id=21043","footnotes":""},"class_list":["post-21056","page","type-page","status-publish","has-post-thumbnail","hentry","en-US"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Braveheart Bio S-1: Never Ran a Trial of Its Own | Tomorrow Access<\/title>\n<meta name=\"description\" content=\"A U.S. startup licensed an oral heart drug discovered by a Chinese pharmaceutical company, taking exclusive rights everywhere outside Greater China, and is now going public. It has never designed or run a clinical trial itself. Zero revenue, an accumulated deficit of about $80.3 million, and a16z Bio among its backers. Decoded from the S-1.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tomorrowaccess.com\/en\/s-1-journal\/braveheart-2026\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Braveheart Bio S-1: Never Ran a Trial of Its Own | Tomorrow Access\" \/>\n<meta property=\"og:description\" content=\"A U.S. startup licensed an oral heart drug discovered by a Chinese pharmaceutical company, taking exclusive rights everywhere outside Greater China, and is now going public. It has never designed or run a clinical trial itself. Zero revenue, an accumulated deficit of about $80.3 million, and a16z Bio among its backers. Decoded from the S-1.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tomorrowaccess.com\/en\/s-1-journal\/braveheart-2026\" \/>\n<meta property=\"og:site_name\" content=\"Tomorrow Access\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TomorrowAccess\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-27T05:19:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tomorrowaccess.com\/wp-content\/uploads\/2026\/07\/braveheart-en-og-dark.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/tomorrowaccess.com\/wp-content\/uploads\/2026\/07\/braveheart-en-og-dark.png\" \/>\n<meta name=\"twitter:site\" content=\"@TomorrowAccess\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/tomorrowaccess.com\\\/en\\\/s-1-journal\\\/braveheart-2026\",\"url\":\"https:\\\/\\\/tomorrowaccess.com\\\/en\\\/s-1-journal\\\/braveheart-2026\",\"name\":\"Braveheart Bio S-1: Never Ran a Trial of Its Own | Tomorrow Access\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/tomorrowaccess.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/tomorrowaccess.com\\\/en\\\/s-1-journal\\\/braveheart-2026#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/tomorrowaccess.com\\\/en\\\/s-1-journal\\\/braveheart-2026#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/tomorrowaccess.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/s1-card-braveheart-2026-en.jpg\",\"datePublished\":\"2026-07-29T01:20:21+00:00\",\"dateModified\":\"2026-10-27T05:19:56+00:00\",\"description\":\"A U.S. startup licensed an oral heart drug discovered by a Chinese pharmaceutical company, taking exclusive rights everywhere outside Greater China, and is now going public. It has never designed or run a clinical trial itself. Zero revenue, an accumulated deficit of about $80.3 million, and a16z Bio among its backers. Decoded from the S-1.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/tomorrowaccess.com\\\/en\\\/s-1-journal\\\/braveheart-2026#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/tomorrowaccess.com\\\/en\\\/s-1-journal\\\/braveheart-2026\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/tomorrowaccess.com\\\/en\\\/s-1-journal\\\/braveheart-2026#primaryimage\",\"url\":\"https:\\\/\\\/tomorrowaccess.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/s1-card-braveheart-2026-en.jpg\",\"contentUrl\":\"https:\\\/\\\/tomorrowaccess.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/s1-card-braveheart-2026-en.jpg\",\"width\":1536,\"height\":1024,\"caption\":\"S-1\u30b8\u30e3\u30fc\u30ca\u30eb Braveheart\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/tomorrowaccess.com\\\/en\\\/s-1-journal\\\/braveheart-2026#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u30db\u30fc\u30e0\",\"item\":\"https:\\\/\\\/tomorrowaccess.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"S-1 Journal \u2014 Every S-1, Explained Through the Same 10 Questions\",\"item\":\"https:\\\/\\\/tomorrowaccess.com\\\/en\\\/s-1-journal\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"It Didn&rsquo;t Invent the Drug. It Didn&rsquo;t Run the Trials. It In-Licensed the Rest-of-World Rights.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/tomorrowaccess.com\\\/#website\",\"url\":\"https:\\\/\\\/tomorrowaccess.com\\\/\",\"name\":\"Tomorrow Access\",\"description\":\"Tomorrow Access Homepage\",\"publisher\":{\"@id\":\"https:\\\/\\\/tomorrowaccess.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/tomorrowaccess.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/tomorrowaccess.com\\\/#organization\",\"name\":\"Tomorrow Access\",\"url\":\"https:\\\/\\\/tomorrowaccess.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/tomorrowaccess.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/tomorrowaccess.com\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/ta-ogp.jpg\",\"contentUrl\":\"https:\\\/\\\/tomorrowaccess.com\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/ta-ogp.jpg\",\"width\":2400,\"height\":1260,\"caption\":\"Tomorrow Access\"},\"image\":{\"@id\":\"https:\\\/\\\/tomorrowaccess.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/TomorrowAccess\",\"https:\\\/\\\/x.com\\\/TomorrowAccess\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/tomorrow-access\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCz2iUaHKT-gK0ijM0_iFDeA\"],\"legalName\":\"Tomorrow Access LLC\",\"alternateName\":[\"\u30c8\u30a5\u30e2\u30ed\u30fc\u30a2\u30af\u30bb\u30b9\",\"Tomorrow Access LLC\"],\"description\":\"Silicon Valley-based consulting firm supporting Japanese companies with U.S. expansion, new business development and corporate venture capital (CVC), and mentoring startups.\",\"foundingDate\":\"2021\",\"slogan\":\"BUILD YOUR OWN PATH\",\"address\":{\"@type\":\"PostalAddress\",\"addressRegion\":\"CA\",\"addressCountry\":\"US\"},\"areaServed\":[{\"@type\":\"Country\",\"name\":\"United States\"},{\"@type\":\"Country\",\"name\":\"Japan\"}],\"knowsLanguage\":[\"ja\",\"en\"],\"knowsAbout\":[\"Silicon Valley\",\"U.S. market entry for Japanese companies\",\"Corporate venture capital (CVC)\",\"New business development\",\"Startup investment\",\"Startup mentoring\"],\"founder\":{\"@id\":\"https:\\\/\\\/tomorrowaccess.com\\\/#\\\/schema\\\/person\\\/ken-sobajima\"},\"contactPoint\":{\"@type\":\"ContactPoint\",\"contactType\":\"sales\",\"url\":\"https:\\\/\\\/tomorrowaccess.com\\\/en\\\/contact\",\"availableLanguage\":[\"ja\",\"en\"]}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/tomorrowaccess.com\\\/#\\\/schema\\\/person\\\/ken-sobajima\",\"name\":\"Ken Sobajima\",\"alternateName\":\"\u508d\u5cf6 \u5065\u53cb\",\"jobTitle\":\"Founder & CEO\",\"worksFor\":{\"@id\":\"https:\\\/\\\/tomorrowaccess.com\\\/#organization\"},\"description\":\"Founder & CEO of Tomorrow Access. 25 years at a major Japanese telecom, including heading U.S. investments for its corporate venture fund; based in Silicon Valley since 2015.\",\"award\":[\"Global Corporate Venturing Rising Stars 2019\",\"Global Corporate Venturing Top 50 Emerging Leaders 2021\"],\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/in\\\/sobazy\\\/\"],\"knowsLanguage\":[\"ja\",\"en\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Braveheart Bio S-1: Never Ran a Trial of Its Own | Tomorrow Access","description":"A U.S. startup licensed an oral heart drug discovered by a Chinese pharmaceutical company, taking exclusive rights everywhere outside Greater China, and is now going public. It has never designed or run a clinical trial itself. Zero revenue, an accumulated deficit of about $80.3 million, and a16z Bio among its backers. Decoded from the S-1.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tomorrowaccess.com\/en\/s-1-journal\/braveheart-2026","og_locale":"en_US","og_type":"article","og_title":"Braveheart Bio S-1: Never Ran a Trial of Its Own | Tomorrow Access","og_description":"A U.S. startup licensed an oral heart drug discovered by a Chinese pharmaceutical company, taking exclusive rights everywhere outside Greater China, and is now going public. It has never designed or run a clinical trial itself. Zero revenue, an accumulated deficit of about $80.3 million, and a16z Bio among its backers. Decoded from the S-1.","og_url":"https:\/\/tomorrowaccess.com\/en\/s-1-journal\/braveheart-2026","og_site_name":"Tomorrow Access","article_publisher":"https:\/\/www.facebook.com\/TomorrowAccess","article_modified_time":"2026-10-27T05:19:56+00:00","og_image":[{"url":"https:\/\/tomorrowaccess.com\/wp-content\/uploads\/2026\/07\/braveheart-en-og-dark.png","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_image":"https:\/\/tomorrowaccess.com\/wp-content\/uploads\/2026\/07\/braveheart-en-og-dark.png","twitter_site":"@TomorrowAccess","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/tomorrowaccess.com\/en\/s-1-journal\/braveheart-2026","url":"https:\/\/tomorrowaccess.com\/en\/s-1-journal\/braveheart-2026","name":"Braveheart Bio S-1: Never Ran a Trial of Its Own | Tomorrow Access","isPartOf":{"@id":"https:\/\/tomorrowaccess.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tomorrowaccess.com\/en\/s-1-journal\/braveheart-2026#primaryimage"},"image":{"@id":"https:\/\/tomorrowaccess.com\/en\/s-1-journal\/braveheart-2026#primaryimage"},"thumbnailUrl":"https:\/\/tomorrowaccess.com\/wp-content\/uploads\/2026\/10\/s1-card-braveheart-2026-en.jpg","datePublished":"2026-07-29T01:20:21+00:00","dateModified":"2026-10-27T05:19:56+00:00","description":"A U.S. startup licensed an oral heart drug discovered by a Chinese pharmaceutical company, taking exclusive rights everywhere outside Greater China, and is now going public. It has never designed or run a clinical trial itself. Zero revenue, an accumulated deficit of about $80.3 million, and a16z Bio among its backers. Decoded from the S-1.","breadcrumb":{"@id":"https:\/\/tomorrowaccess.com\/en\/s-1-journal\/braveheart-2026#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tomorrowaccess.com\/en\/s-1-journal\/braveheart-2026"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tomorrowaccess.com\/en\/s-1-journal\/braveheart-2026#primaryimage","url":"https:\/\/tomorrowaccess.com\/wp-content\/uploads\/2026\/10\/s1-card-braveheart-2026-en.jpg","contentUrl":"https:\/\/tomorrowaccess.com\/wp-content\/uploads\/2026\/10\/s1-card-braveheart-2026-en.jpg","width":1536,"height":1024,"caption":"S-1\u30b8\u30e3\u30fc\u30ca\u30eb Braveheart"},{"@type":"BreadcrumbList","@id":"https:\/\/tomorrowaccess.com\/en\/s-1-journal\/braveheart-2026#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u30db\u30fc\u30e0","item":"https:\/\/tomorrowaccess.com\/en\/"},{"@type":"ListItem","position":2,"name":"S-1 Journal \u2014 Every S-1, Explained Through the Same 10 Questions","item":"https:\/\/tomorrowaccess.com\/en\/s-1-journal"},{"@type":"ListItem","position":3,"name":"It Didn&rsquo;t Invent the Drug. It Didn&rsquo;t Run the Trials. It In-Licensed the Rest-of-World Rights."}]},{"@type":"WebSite","@id":"https:\/\/tomorrowaccess.com\/#website","url":"https:\/\/tomorrowaccess.com\/","name":"Tomorrow Access","description":"Tomorrow Access Homepage","publisher":{"@id":"https:\/\/tomorrowaccess.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tomorrowaccess.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/tomorrowaccess.com\/#organization","name":"Tomorrow Access","url":"https:\/\/tomorrowaccess.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tomorrowaccess.com\/#\/schema\/logo\/image\/","url":"https:\/\/tomorrowaccess.com\/wp-content\/uploads\/2022\/10\/ta-ogp.jpg","contentUrl":"https:\/\/tomorrowaccess.com\/wp-content\/uploads\/2022\/10\/ta-ogp.jpg","width":2400,"height":1260,"caption":"Tomorrow Access"},"image":{"@id":"https:\/\/tomorrowaccess.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/TomorrowAccess","https:\/\/x.com\/TomorrowAccess","https:\/\/www.linkedin.com\/company\/tomorrow-access","https:\/\/www.youtube.com\/channel\/UCz2iUaHKT-gK0ijM0_iFDeA"],"legalName":"Tomorrow Access LLC","alternateName":["\u30c8\u30a5\u30e2\u30ed\u30fc\u30a2\u30af\u30bb\u30b9","Tomorrow Access LLC"],"description":"Silicon Valley-based consulting firm supporting Japanese companies with U.S. expansion, new business development and corporate venture capital (CVC), and mentoring startups.","foundingDate":"2021","slogan":"BUILD YOUR OWN PATH","address":{"@type":"PostalAddress","addressRegion":"CA","addressCountry":"US"},"areaServed":[{"@type":"Country","name":"United States"},{"@type":"Country","name":"Japan"}],"knowsLanguage":["ja","en"],"knowsAbout":["Silicon Valley","U.S. market entry for Japanese companies","Corporate venture capital (CVC)","New business development","Startup investment","Startup mentoring"],"founder":{"@id":"https:\/\/tomorrowaccess.com\/#\/schema\/person\/ken-sobajima"},"contactPoint":{"@type":"ContactPoint","contactType":"sales","url":"https:\/\/tomorrowaccess.com\/en\/contact","availableLanguage":["ja","en"]}},{"@type":"Person","@id":"https:\/\/tomorrowaccess.com\/#\/schema\/person\/ken-sobajima","name":"Ken Sobajima","alternateName":"\u508d\u5cf6 \u5065\u53cb","jobTitle":"Founder & CEO","worksFor":{"@id":"https:\/\/tomorrowaccess.com\/#organization"},"description":"Founder & CEO of Tomorrow Access. 25 years at a major Japanese telecom, including heading U.S. investments for its corporate venture fund; based in Silicon Valley since 2015.","award":["Global Corporate Venturing Rising Stars 2019","Global Corporate Venturing Top 50 Emerging Leaders 2021"],"sameAs":["https:\/\/www.linkedin.com\/in\/sobazy\/"],"knowsLanguage":["ja","en"]}]}},"uagb_featured_image_src":{"full":["https:\/\/tomorrowaccess.com\/wp-content\/uploads\/2026\/10\/s1-card-braveheart-2026-en.jpg",1536,1024,false],"thumbnail":["https:\/\/tomorrowaccess.com\/wp-content\/uploads\/2026\/10\/s1-card-braveheart-2026-en-150x150.jpg",150,150,true],"medium":["https:\/\/tomorrowaccess.com\/wp-content\/uploads\/2026\/10\/s1-card-braveheart-2026-en-300x200.jpg",300,200,true],"medium_large":["https:\/\/tomorrowaccess.com\/wp-content\/uploads\/2026\/10\/s1-card-braveheart-2026-en-768x512.jpg",768,512,true],"large":["https:\/\/tomorrowaccess.com\/wp-content\/uploads\/2026\/10\/s1-card-braveheart-2026-en-1024x683.jpg",1024,683,true],"1536x1536":["https:\/\/tomorrowaccess.com\/wp-content\/uploads\/2026\/10\/s1-card-braveheart-2026-en.jpg",1536,1024,false],"2048x2048":["https:\/\/tomorrowaccess.com\/wp-content\/uploads\/2026\/10\/s1-card-braveheart-2026-en.jpg",1536,1024,false]},"uagb_author_info":{"display_name":"Ken","author_link":"https:\/\/tomorrowaccess.com\/news\/author\/ken"},"uagb_comment_info":0,"uagb_excerpt":"S-1 Journal The 10 Questions | Every S-1, decoded throu&hellip;","_links":{"self":[{"href":"https:\/\/tomorrowaccess.com\/wp-json\/wp\/v2\/pages\/21056","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tomorrowaccess.com\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/tomorrowaccess.com\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/tomorrowaccess.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/tomorrowaccess.com\/wp-json\/wp\/v2\/comments?post=21056"}],"version-history":[{"count":1,"href":"https:\/\/tomorrowaccess.com\/wp-json\/wp\/v2\/pages\/21056\/revisions"}],"predecessor-version":[{"id":23700,"href":"https:\/\/tomorrowaccess.com\/wp-json\/wp\/v2\/pages\/21056\/revisions\/23700"}],"up":[{"embeddable":true,"href":"https:\/\/tomorrowaccess.com\/wp-json\/wp\/v2\/pages\/20744"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tomorrowaccess.com\/wp-json\/wp\/v2\/media\/24365"}],"wp:attachment":[{"href":"https:\/\/tomorrowaccess.com\/wp-json\/wp\/v2\/media?parent=21056"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}